Does oral polio vaccine have non-specific effects on all-cause mortality? Natural experiments within a randomised controlled trial of early measles vaccine
BackgroundBCG and measles vaccine (MV) may have beneficial non-specific effects (NSEs). If an unplanned intervention with a vaccine (a natural experiment) modifies the estimated effect in a randomised controlled trial (RCT), this suggests NSEs. We used this approach to test NSEs of triple oral polio...
Gespeichert in:
Veröffentlicht in: | BMJ open 2016-12, Vol.6 (12), p.e013335-e013335 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | e013335 |
---|---|
container_issue | 12 |
container_start_page | e013335 |
container_title | BMJ open |
container_volume | 6 |
creator | Aaby, Peter Andersen, Andreas Martins, Cesário L Fisker, Ane B Rodrigues, Amabelia Whittle, Hilton C Benn, Christine S |
description | BackgroundBCG and measles vaccine (MV) may have beneficial non-specific effects (NSEs). If an unplanned intervention with a vaccine (a natural experiment) modifies the estimated effect in a randomised controlled trial (RCT), this suggests NSEs. We used this approach to test NSEs of triple oral polio vaccine (OPV).MethodsDuring an RCT of 2 doses of MV at 4.5 and 9 months versus 1 dose of MV at 9 months of age, we experienced 2 natural experiments with OPV. We assessed whether these OPV experiments modified the effect of 2-dose MV in the MV trial.SettingMV RCT conducted in urban Guinea-Bissau 2003–2009.InterventionsNatural experiments with OPV due to missing vaccine and the implementation of OPV campaigns.Main outcome measureChanges in the mortality rate ratio (MRR) for 2-dose MV versus 1-dose MV.ResultsFirst, the MRR (2-dose/1-dose MV) overall was 0.70 (0.52 to 0.94), but the MRR was 1.04 (0.53 to 2.04) when OPV at birth (OPV0) was not given, suggesting that early priming with OPV was important for the effect of 2-dose MV. The effect of OPV0 depended on age of administration; the MRR (2-dose/1-dose MV) was 0.45 (0.29 to 0.71) for children receiving OPV0 in the first week of life, but 3.63 (0.87 to 15.2) for those receiving OPV0 after the first month of life (p=0.007, test of no interaction). Second, campaign-OPV may have reduced the difference between the randomisation groups since the MRR (2-dose/1-dose MV) was 0.60 (0.42 to 0.85) for children who had not received campaign-OPV before RCT-enrolment versus 0.72 (0.23 to 2.31) and 1.42 (0.70 to 2.90) for children who had received 1 or 2 doses of campaign-OPV-before-enrolment, respectively.ConclusionsBissau had no polio infection during this trial, so OPV0 and campaign-OPV may have NSEs since they modified the effect of 2-dose MV in an RCT. Different interventions may interact to a much larger effect than usually assumed. |
doi_str_mv | 10.1136/bmjopen-2016-013335 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5223718</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1852786931</sourcerecordid><originalsourceid>FETCH-LOGICAL-b472t-d522885633f056d9867e2c8724c08cbdf2c4afa613914ad1f8bedc81cd98b0a63</originalsourceid><addsrcrecordid>eNqNkc1u1DAUhSMEolXpEyAhS2zYpPgnTpwNCJVfqYINrC3HuWY8cuxgJ1PmWXhZ7miGqrDCG1u63z0-R6eqnjJ6xZhoXw7TNs0Qa05ZW1MmhJAPqnNOm6ZuqZQP773PqstSthRPI3sp-ePqjCvKmGLivPr1NkEhKZtA5hR8IjtjrY9ANmYHJKZYlxmsd94ScA7sgnAkJoTamrUAmVJeTPDL_jX5bJb1oAM_Z8h-gojsrV82HnmSTRzT5AuMxKa45BQCPpfscSE5AiaHPZnAlIB2Th6eVI-cCQUuT_dF9e39u6_XH-ubLx8-Xb-5qYem40s9Ss6Vkq0Qjsp27FXbAbeq442lyg6j47YxzrRM9KwxI3NqgNEqZhEdqGnFRfXqqDuvw4QjdI459IwhTN7rZLz-exL9Rn9PO40fi44pFHhxEsjpxwpl0ZjUQggmQlqLZkryTrW9YIg-_wfdpjVHjHegWN93vOdIiSNlcyolg7szw6g-9K9P_etD__rYP249u5_jbudP2whcHQHc_i_F3xvAwBc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1851997292</pqid></control><display><type>article</type><title>Does oral polio vaccine have non-specific effects on all-cause mortality? Natural experiments within a randomised controlled trial of early measles vaccine</title><source>BMJ Open Access Journals</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Aaby, Peter ; Andersen, Andreas ; Martins, Cesário L ; Fisker, Ane B ; Rodrigues, Amabelia ; Whittle, Hilton C ; Benn, Christine S</creator><creatorcontrib>Aaby, Peter ; Andersen, Andreas ; Martins, Cesário L ; Fisker, Ane B ; Rodrigues, Amabelia ; Whittle, Hilton C ; Benn, Christine S</creatorcontrib><description>BackgroundBCG and measles vaccine (MV) may have beneficial non-specific effects (NSEs). If an unplanned intervention with a vaccine (a natural experiment) modifies the estimated effect in a randomised controlled trial (RCT), this suggests NSEs. We used this approach to test NSEs of triple oral polio vaccine (OPV).MethodsDuring an RCT of 2 doses of MV at 4.5 and 9 months versus 1 dose of MV at 9 months of age, we experienced 2 natural experiments with OPV. We assessed whether these OPV experiments modified the effect of 2-dose MV in the MV trial.SettingMV RCT conducted in urban Guinea-Bissau 2003–2009.InterventionsNatural experiments with OPV due to missing vaccine and the implementation of OPV campaigns.Main outcome measureChanges in the mortality rate ratio (MRR) for 2-dose MV versus 1-dose MV.ResultsFirst, the MRR (2-dose/1-dose MV) overall was 0.70 (0.52 to 0.94), but the MRR was 1.04 (0.53 to 2.04) when OPV at birth (OPV0) was not given, suggesting that early priming with OPV was important for the effect of 2-dose MV. The effect of OPV0 depended on age of administration; the MRR (2-dose/1-dose MV) was 0.45 (0.29 to 0.71) for children receiving OPV0 in the first week of life, but 3.63 (0.87 to 15.2) for those receiving OPV0 after the first month of life (p=0.007, test of no interaction). Second, campaign-OPV may have reduced the difference between the randomisation groups since the MRR (2-dose/1-dose MV) was 0.60 (0.42 to 0.85) for children who had not received campaign-OPV before RCT-enrolment versus 0.72 (0.23 to 2.31) and 1.42 (0.70 to 2.90) for children who had received 1 or 2 doses of campaign-OPV-before-enrolment, respectively.ConclusionsBissau had no polio infection during this trial, so OPV0 and campaign-OPV may have NSEs since they modified the effect of 2-dose MV in an RCT. Different interventions may interact to a much larger effect than usually assumed.</description><identifier>ISSN: 2044-6055</identifier><identifier>EISSN: 2044-6055</identifier><identifier>DOI: 10.1136/bmjopen-2016-013335</identifier><identifier>PMID: 28011813</identifier><language>eng</language><publisher>England: BMJ Publishing Group LTD</publisher><subject>Age ; Age Factors ; Cause of Death ; Child Mortality ; Child, Preschool ; Drug Administration Schedule ; Experiments ; Female ; Global Health ; Guinea-Bissau - epidemiology ; Humans ; Immune System - growth & development ; Immunity, Heterologous ; Infant ; Infant Mortality ; Infant, Newborn ; Infections ; Male ; Measles ; Measles Vaccine ; Mortality ; Poliomyelitis ; Poliomyelitis - prevention & control ; Poliovirus Vaccine, Oral - administration & dosage ; Poliovirus Vaccine, Oral - immunology ; Protective Factors ; Tetanus ; Treatment Outcome ; Vaccination ; Vaccines ; Vitamin A ; Whooping cough</subject><ispartof>BMJ open, 2016-12, Vol.6 (12), p.e013335-e013335</ispartof><rights>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing</rights><rights>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.</rights><rights>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ 2016 This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b472t-d522885633f056d9867e2c8724c08cbdf2c4afa613914ad1f8bedc81cd98b0a63</citedby><cites>FETCH-LOGICAL-b472t-d522885633f056d9867e2c8724c08cbdf2c4afa613914ad1f8bedc81cd98b0a63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://bmjopen.bmj.com/content/6/12/e013335.full.pdf$$EPDF$$P50$$Gbmj$$Hfree_for_read</linktopdf><linktohtml>$$Uhttp://bmjopen.bmj.com/content/6/12/e013335.full$$EHTML$$P50$$Gbmj$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27549,27550,27924,27925,53791,53793,77601,77632</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28011813$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Aaby, Peter</creatorcontrib><creatorcontrib>Andersen, Andreas</creatorcontrib><creatorcontrib>Martins, Cesário L</creatorcontrib><creatorcontrib>Fisker, Ane B</creatorcontrib><creatorcontrib>Rodrigues, Amabelia</creatorcontrib><creatorcontrib>Whittle, Hilton C</creatorcontrib><creatorcontrib>Benn, Christine S</creatorcontrib><title>Does oral polio vaccine have non-specific effects on all-cause mortality? Natural experiments within a randomised controlled trial of early measles vaccine</title><title>BMJ open</title><addtitle>BMJ Open</addtitle><description>BackgroundBCG and measles vaccine (MV) may have beneficial non-specific effects (NSEs). If an unplanned intervention with a vaccine (a natural experiment) modifies the estimated effect in a randomised controlled trial (RCT), this suggests NSEs. We used this approach to test NSEs of triple oral polio vaccine (OPV).MethodsDuring an RCT of 2 doses of MV at 4.5 and 9 months versus 1 dose of MV at 9 months of age, we experienced 2 natural experiments with OPV. We assessed whether these OPV experiments modified the effect of 2-dose MV in the MV trial.SettingMV RCT conducted in urban Guinea-Bissau 2003–2009.InterventionsNatural experiments with OPV due to missing vaccine and the implementation of OPV campaigns.Main outcome measureChanges in the mortality rate ratio (MRR) for 2-dose MV versus 1-dose MV.ResultsFirst, the MRR (2-dose/1-dose MV) overall was 0.70 (0.52 to 0.94), but the MRR was 1.04 (0.53 to 2.04) when OPV at birth (OPV0) was not given, suggesting that early priming with OPV was important for the effect of 2-dose MV. The effect of OPV0 depended on age of administration; the MRR (2-dose/1-dose MV) was 0.45 (0.29 to 0.71) for children receiving OPV0 in the first week of life, but 3.63 (0.87 to 15.2) for those receiving OPV0 after the first month of life (p=0.007, test of no interaction). Second, campaign-OPV may have reduced the difference between the randomisation groups since the MRR (2-dose/1-dose MV) was 0.60 (0.42 to 0.85) for children who had not received campaign-OPV before RCT-enrolment versus 0.72 (0.23 to 2.31) and 1.42 (0.70 to 2.90) for children who had received 1 or 2 doses of campaign-OPV-before-enrolment, respectively.ConclusionsBissau had no polio infection during this trial, so OPV0 and campaign-OPV may have NSEs since they modified the effect of 2-dose MV in an RCT. Different interventions may interact to a much larger effect than usually assumed.</description><subject>Age</subject><subject>Age Factors</subject><subject>Cause of Death</subject><subject>Child Mortality</subject><subject>Child, Preschool</subject><subject>Drug Administration Schedule</subject><subject>Experiments</subject><subject>Female</subject><subject>Global Health</subject><subject>Guinea-Bissau - epidemiology</subject><subject>Humans</subject><subject>Immune System - growth & development</subject><subject>Immunity, Heterologous</subject><subject>Infant</subject><subject>Infant Mortality</subject><subject>Infant, Newborn</subject><subject>Infections</subject><subject>Male</subject><subject>Measles</subject><subject>Measles Vaccine</subject><subject>Mortality</subject><subject>Poliomyelitis</subject><subject>Poliomyelitis - prevention & control</subject><subject>Poliovirus Vaccine, Oral - administration & dosage</subject><subject>Poliovirus Vaccine, Oral - immunology</subject><subject>Protective Factors</subject><subject>Tetanus</subject><subject>Treatment Outcome</subject><subject>Vaccination</subject><subject>Vaccines</subject><subject>Vitamin A</subject><subject>Whooping cough</subject><issn>2044-6055</issn><issn>2044-6055</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>9YT</sourceid><sourceid>ACMMV</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqNkc1u1DAUhSMEolXpEyAhS2zYpPgnTpwNCJVfqYINrC3HuWY8cuxgJ1PmWXhZ7miGqrDCG1u63z0-R6eqnjJ6xZhoXw7TNs0Qa05ZW1MmhJAPqnNOm6ZuqZQP773PqstSthRPI3sp-ePqjCvKmGLivPr1NkEhKZtA5hR8IjtjrY9ANmYHJKZYlxmsd94ScA7sgnAkJoTamrUAmVJeTPDL_jX5bJb1oAM_Z8h-gojsrV82HnmSTRzT5AuMxKa45BQCPpfscSE5AiaHPZnAlIB2Th6eVI-cCQUuT_dF9e39u6_XH-ubLx8-Xb-5qYem40s9Ss6Vkq0Qjsp27FXbAbeq442lyg6j47YxzrRM9KwxI3NqgNEqZhEdqGnFRfXqqDuvw4QjdI459IwhTN7rZLz-exL9Rn9PO40fi44pFHhxEsjpxwpl0ZjUQggmQlqLZkryTrW9YIg-_wfdpjVHjHegWN93vOdIiSNlcyolg7szw6g-9K9P_etD__rYP249u5_jbudP2whcHQHc_i_F3xvAwBc</recordid><startdate>20161223</startdate><enddate>20161223</enddate><creator>Aaby, Peter</creator><creator>Andersen, Andreas</creator><creator>Martins, Cesário L</creator><creator>Fisker, Ane B</creator><creator>Rodrigues, Amabelia</creator><creator>Whittle, Hilton C</creator><creator>Benn, Christine S</creator><general>BMJ Publishing Group LTD</general><general>BMJ Publishing Group</general><scope>9YT</scope><scope>ACMMV</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20161223</creationdate><title>Does oral polio vaccine have non-specific effects on all-cause mortality? Natural experiments within a randomised controlled trial of early measles vaccine</title><author>Aaby, Peter ; Andersen, Andreas ; Martins, Cesário L ; Fisker, Ane B ; Rodrigues, Amabelia ; Whittle, Hilton C ; Benn, Christine S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b472t-d522885633f056d9867e2c8724c08cbdf2c4afa613914ad1f8bedc81cd98b0a63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Age</topic><topic>Age Factors</topic><topic>Cause of Death</topic><topic>Child Mortality</topic><topic>Child, Preschool</topic><topic>Drug Administration Schedule</topic><topic>Experiments</topic><topic>Female</topic><topic>Global Health</topic><topic>Guinea-Bissau - epidemiology</topic><topic>Humans</topic><topic>Immune System - growth & development</topic><topic>Immunity, Heterologous</topic><topic>Infant</topic><topic>Infant Mortality</topic><topic>Infant, Newborn</topic><topic>Infections</topic><topic>Male</topic><topic>Measles</topic><topic>Measles Vaccine</topic><topic>Mortality</topic><topic>Poliomyelitis</topic><topic>Poliomyelitis - prevention & control</topic><topic>Poliovirus Vaccine, Oral - administration & dosage</topic><topic>Poliovirus Vaccine, Oral - immunology</topic><topic>Protective Factors</topic><topic>Tetanus</topic><topic>Treatment Outcome</topic><topic>Vaccination</topic><topic>Vaccines</topic><topic>Vitamin A</topic><topic>Whooping cough</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Aaby, Peter</creatorcontrib><creatorcontrib>Andersen, Andreas</creatorcontrib><creatorcontrib>Martins, Cesário L</creatorcontrib><creatorcontrib>Fisker, Ane B</creatorcontrib><creatorcontrib>Rodrigues, Amabelia</creatorcontrib><creatorcontrib>Whittle, Hilton C</creatorcontrib><creatorcontrib>Benn, Christine S</creatorcontrib><collection>BMJ Open Access Journals</collection><collection>BMJ Journals:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BMJ open</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Aaby, Peter</au><au>Andersen, Andreas</au><au>Martins, Cesário L</au><au>Fisker, Ane B</au><au>Rodrigues, Amabelia</au><au>Whittle, Hilton C</au><au>Benn, Christine S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Does oral polio vaccine have non-specific effects on all-cause mortality? Natural experiments within a randomised controlled trial of early measles vaccine</atitle><jtitle>BMJ open</jtitle><addtitle>BMJ Open</addtitle><date>2016-12-23</date><risdate>2016</risdate><volume>6</volume><issue>12</issue><spage>e013335</spage><epage>e013335</epage><pages>e013335-e013335</pages><issn>2044-6055</issn><eissn>2044-6055</eissn><abstract>BackgroundBCG and measles vaccine (MV) may have beneficial non-specific effects (NSEs). If an unplanned intervention with a vaccine (a natural experiment) modifies the estimated effect in a randomised controlled trial (RCT), this suggests NSEs. We used this approach to test NSEs of triple oral polio vaccine (OPV).MethodsDuring an RCT of 2 doses of MV at 4.5 and 9 months versus 1 dose of MV at 9 months of age, we experienced 2 natural experiments with OPV. We assessed whether these OPV experiments modified the effect of 2-dose MV in the MV trial.SettingMV RCT conducted in urban Guinea-Bissau 2003–2009.InterventionsNatural experiments with OPV due to missing vaccine and the implementation of OPV campaigns.Main outcome measureChanges in the mortality rate ratio (MRR) for 2-dose MV versus 1-dose MV.ResultsFirst, the MRR (2-dose/1-dose MV) overall was 0.70 (0.52 to 0.94), but the MRR was 1.04 (0.53 to 2.04) when OPV at birth (OPV0) was not given, suggesting that early priming with OPV was important for the effect of 2-dose MV. The effect of OPV0 depended on age of administration; the MRR (2-dose/1-dose MV) was 0.45 (0.29 to 0.71) for children receiving OPV0 in the first week of life, but 3.63 (0.87 to 15.2) for those receiving OPV0 after the first month of life (p=0.007, test of no interaction). Second, campaign-OPV may have reduced the difference between the randomisation groups since the MRR (2-dose/1-dose MV) was 0.60 (0.42 to 0.85) for children who had not received campaign-OPV before RCT-enrolment versus 0.72 (0.23 to 2.31) and 1.42 (0.70 to 2.90) for children who had received 1 or 2 doses of campaign-OPV-before-enrolment, respectively.ConclusionsBissau had no polio infection during this trial, so OPV0 and campaign-OPV may have NSEs since they modified the effect of 2-dose MV in an RCT. Different interventions may interact to a much larger effect than usually assumed.</abstract><cop>England</cop><pub>BMJ Publishing Group LTD</pub><pmid>28011813</pmid><doi>10.1136/bmjopen-2016-013335</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2044-6055 |
ispartof | BMJ open, 2016-12, Vol.6 (12), p.e013335-e013335 |
issn | 2044-6055 2044-6055 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5223718 |
source | BMJ Open Access Journals; MEDLINE; DOAJ Directory of Open Access Journals; PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central |
subjects | Age Age Factors Cause of Death Child Mortality Child, Preschool Drug Administration Schedule Experiments Female Global Health Guinea-Bissau - epidemiology Humans Immune System - growth & development Immunity, Heterologous Infant Infant Mortality Infant, Newborn Infections Male Measles Measles Vaccine Mortality Poliomyelitis Poliomyelitis - prevention & control Poliovirus Vaccine, Oral - administration & dosage Poliovirus Vaccine, Oral - immunology Protective Factors Tetanus Treatment Outcome Vaccination Vaccines Vitamin A Whooping cough |
title | Does oral polio vaccine have non-specific effects on all-cause mortality? Natural experiments within a randomised controlled trial of early measles vaccine |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T16%3A36%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Does%20oral%20polio%20vaccine%20have%20non-specific%20effects%20on%20all-cause%20mortality?%20Natural%20experiments%20within%20a%20randomised%20controlled%20trial%20of%20early%20measles%20vaccine&rft.jtitle=BMJ%20open&rft.au=Aaby,%20Peter&rft.date=2016-12-23&rft.volume=6&rft.issue=12&rft.spage=e013335&rft.epage=e013335&rft.pages=e013335-e013335&rft.issn=2044-6055&rft.eissn=2044-6055&rft_id=info:doi/10.1136/bmjopen-2016-013335&rft_dat=%3Cproquest_pubme%3E1852786931%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1851997292&rft_id=info:pmid/28011813&rfr_iscdi=true |